A
Allergan, Senju Pharmaceutical, Kyorin Pharmaceutical
Direct purchasers of certain eye care products may have been eligible for a $9 million antitrust class action settlement.
ClosedUnited States-wideClaim status: Claim window closedPayout: Closed settlementNo longer claimable
About this settlement
Alleged antitrust violations related to the pricing and sale of Zymar and Zymaxid eye care products.
This settlement resolved claims against Allergan, Senju Pharmaceutical, and Kyorin Pharmaceutical regarding alleged antitrust violations involving eye care products Zymar and Zymaxid. The $9 million fund was for direct purchasers of these products.
Who qualifies
- Direct purchasers of Zymar or Zymaxid eye care products from Allergan, Senju Pharmaceutical, or Kyorin Pharmaceutical.
Closed settlement
Claim status: Claim window closed